The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2024 | Treating R/R CLL: the value of BTKis and venetoclax
Wojciech Jurczak, MD, PhD, Jagiellonian University, Krakow, Poland, discusses the treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). He recommends BTK inhibitors (BTKis) for patients with deletion 17p or TP53 mutations and mentions the value of BTKis in combination with venetoclax. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
